Pyxis Oncology is trading 10.03% up now at $3.29, with the move appearing primarily sector-driven after Moderna and Merck reported positive Phase 3 melanoma vaccine results.
- No new company-specific announcement was identified on August 19, 2026.
- Its latest update, released August 13, covered second-quarter results, MICVO development, and financing support for upcoming clinical milestones.